Orgaran (Danaparoid Sodium)

Orgaran is an anticoagulant that acts within the coagulation cascade to prevent clot formation in high‑risk settings.

• Heparin‑induced thrombocytopenia (HIT): Provides safe prophylaxis and treatment of venous thromboembolism without cross‑reactivity to heparin antibodies.
• Orthopedic surgery: Prevents deep‑vein thrombosis in patients where HIT risk precludes standard heparin use.
• Vascular surgery: Reduces incidence of postoperative thrombotic events in HIT‑susceptible individuals.

• Danaparoid sodium exerts its anticoagulant effect by indirectly inhibiting factor Xa and, to a lesser extent, factor IXa through potentiation of antithrombin III activity. This reduces thrombin generation and limits fibrin clot formation, providing anticoagulation without significant interaction with platelet factor 4 antibodies.

Adverse reactions to Danaparoid sodium may range from mild to severe and should be monitored during therapy.

Common Side Effects

• Minor bleeding at infusion site
• Hematuria
• Epistaxis
• Gastrointestinal bleeding
• Bruising or ecchymosis
• Elevated liver enzymes

Serious or Rare Side Effects

• Major hemorrhage (intracranial, gastrointestinal)
• Thrombocytopenia unrelated to HIT
• Hypersensitivity reactions including anaphylaxis
• Disseminated intravascular coagulation (DIC)
• Acute renal failure secondary to bleeding
• Severe skin necrosis at infusion site

When using Orgaran, clinicians should assess patient‑specific risk factors and monitor laboratory parameters.

• Renal impairment: Adjust dosing and monitor renal function closely.
• Hepatic dysfunction: Observe liver enzymes and consider dose modification.
• Concomitant anticoagulants: Evaluate cumulative bleeding risk.
• Recent surgery or trauma: Delay infusion until hemostasis is secured.
• Pregnancy and lactation: Use only if clearly indicated after risk‑benefit evaluation.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Danaparoid sodium can interact with several drug classes, influencing bleeding risk and anticoagulant effectiveness.

Major Interactions (Avoid)

• Direct thrombin inhibitors (e.g., argatroban, dabigatran): combined use markedly increases bleeding risk.
• Factor Xa inhibitors (e.g., rivaroxaban, apixaban): additive anticoagulant effect may lead to severe hemorrhage.

Moderate Interactions (Monitor Closely)

• Antiplatelet agents (aspirin, clopidogrel): may enhance minor bleeding.
• Non‑steroidal anti‑inflamatory NSAIDs: increase gastrointestinal bleeding potential.
• Glycoprotein IIb/IIIa inhibitors: monitor platelet counts and bleeding signs.
• Heparin products: cross‑reactivity risk requires careful laboratory monitoring.
• Vitamin K antagonists (warfarin): overlapping anticoagulation necessitates INR surveillance.